Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Myalept Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Myalept (metreleptin) Prior Authorization Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for Myalept 11.3 mg subcutaneous injection for Boeing commercial plan members. Coverage requires a qualifying indication, clinical documentation, specialist involvement or consultation, absence of contraindications and limitations of use, and dosing within FDA labeling.

    Policy Summary
    PayerPrime Therapeutics
    PolicyMyalept (metreleptin) Prior Authorization Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date11-15-2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing a qualifying indication, required laboratory and treatment history, specialist involvement or consultation, no FDA-labeled contraindication, and dosing within FDA labeling.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial approval duration
    12 monthsRenewal approval duration
    < 12 ng/mLLeptin threshold
    ≥ 200 mg/dLHypertriglyceridemia threshold
    Policy Summary
    PayerPrime Therapeutics
    PolicyMyalept (metreleptin) Prior Authorization Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date11-15-2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing a qualifying indication, required laboratory and treatment history, specialist involvement or consultation, no FDA-labeled contraindication, and dosing within FDA labeling.
    SourceLink
    On This Page
    Coverage CriteriaClinical ThresholdsPrior Authorization and DocumentationPolicy BackgroundKey DefinitionsMyalept Initial ApprovalMyalept RenewalRequired Prior TherapyDose and Quantity Requirements

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥ 30 microU/mL
    Hyperinsulinemia threshold
    11.3 mgTarget strength

    Coverage Criteria

    Initial Therapy Criteria

    Initial therapy is approved when all requirements are met and either the generalized lipodystrophy pathway or another FDA-labeled indication pathway is satisfied.

    Initial therapy

    • Qualifying indication

      • Generalized lipodystrophy pathway

        • Diagnosis and leptin deficiency: The patient has congenital generalized lipodystrophy or acquired generalized lipodystrophy, and leptin deficiency is confirmed by laboratory testing before initiation.Leptin < 12 ng/mL
        • ONE qualifying lipodystrophy complication

          • Diabetes mellitus related to lipodystrophy.
          • Hyperinsulinemia related to lipodystrophy.≥ 30 microU/mL
          • Hypertriglyceridemia related to lipodystrophy.≥ 200 mg/dL
        • Baseline testing and prior treatment: Baseline HbA1c, triglycerides, and fasting insulin levels were measured before initiating the requested agent, and the patient tried and had an inadequate response to the maximum tolerable dose of a conventional agent for complications related to lipodystrophy.
      • Other FDA-labeled indication pathway

        • The patient has another FDA-labeled indication for the requested agent and route of administration.
        • The patient had an inadequate response to lifestyle modification, including diet modification and exercise.
        • The patient will continue lifestyle modifications with the requested agent.
        • No applicable limitation of use: The patient does not have partial lipodystrophy, liver disease including NASH or MASH, HIV-related lipodystrophy, or metabolic disease such as diabetes mellitus or hypertriglyceridemia without evidence of generalized lipodystrophy.
    • Additional initial requirements

      • The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist, or has consulted with such a specialist.
      • The patient does not have an FDA-labeled contraindication to the requested agent.
      • The requested quantity or dose is within FDA labeling for the requested indication.

    Continuation Therapy Criteria

    Renewal therapy is approved when all of the following are met.

    Continuation therapy

    • The patient was previously approved for the requested agent through the plan's prior authorization process.

      Patients not previously approved require initial evaluation review.

    • The patient has demonstrated clinical benefit with the requested agent.
    • The patient will continue lifestyle modifications, including diet and exercise, with the requested agent.
    • The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist, or has consulted with such a specialist.
    • The patient does not have an FDA-labeled contraindication to the requested agent.

    For initial coverage, the patient must meet either the generalized lipodystrophy pathway or another FDA-labeled indication pathway. The generalized lipodystrophy pathway requires congenital or acquired generalized lipodystrophy, laboratory-confirmed leptin deficiency of < 12 ng/mL before treatment, at least one related complication, baseline HbA1c, triglyceride, and fasting insulin measurements, and inadequate response to the maximum tolerable dose of a conventional agent for lipodystrophy-related complications. A qualifying complication is diabetes mellitus, hyperinsulinemia of ≥ 30 microU/mL, or hypertriglyceridemia of ≥ 200 mg/dL.

    For another FDA-labeled indication, the patient must have an inadequate response to diet modification and exercise and continue lifestyle modifications with Myalept. Coverage is not approved for partial lipodystrophy, liver disease including NASH or MASH, HIV-related lipodystrophy, or metabolic disease such as diabetes mellitus or hypertriglyceridemia without evidence of generalized lipodystrophy. Specialist prescribing or consultation is also required.

    Coverage excludes any FDA-labeled contraindication to Myalept. The requested quantity or dose must also remain within FDA labeling for the requested indication; amounts outside labeled dosing or quantity parameters are not approved.

    Clinical Thresholds

    Leptin level
    Required levelLess than 12 ng/mL
    Testing methodConfirmed by laboratory testing
    TimingMeasured before initiating the requested agent
    Hyperinsulinemia
    Qualifying thresholdGreater than or equal to 30 microU/mL
    ConditionHyperinsulinemia related to lipodystrophy
    PathwayQualifying complication under the generalized lipodystrophy pathway

    Prior Authorization and Documentation

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for initial evaluation. Approval requires meeting either the generalized lipodystrophy pathway or another FDA-labeled indication pathway, along with all applicable clinical, prescriber, safety, and dosing requirements.

    • Generalized lipodystrophy pathway: documented diagnosis, confirmed leptin deficiency, qualifying complication, baseline laboratory testing, and inadequate response to a maximum-tolerable-dose conventional agent.
    • Alternative FDA-labeled indication pathway: inadequate response to lifestyle modification, continued diet and exercise, no excluded limitation of use, specialist involvement or consultation, no FDA-labeled contraindication, and FDA-labeled dosing.
    Prior Authorization

    Renewal Prior Authorization Required

    Renewal authorization is required for continued therapy. Renewal approval requires prior plan approval, documented clinical benefit, continued lifestyle modification, appropriate specialist involvement or consultation, no FDA-labeled contraindication, and dosing within FDA labeling.

    • Patients not previously approved through the plan's prior authorization process require initial evaluation review.

    Policy Background

    Myalept contains metreleptin and is evaluated for generalized lipodystrophy or another FDA-labeled indication. For generalized lipodystrophy, coverage review focuses on documented leptin deficiency, a related metabolic complication, baseline metabolic laboratory testing, and inadequate response to conventional treatment. Applicable initial and renewal reviews also require continued lifestyle modification and specialist involvement or consultation.

    Key Definitions

    Congenital generalized lipodystrophy (CGL)
    AbbreviationCGL
    DefinitionA congenital form of generalized lipodystrophy
    Coverage pathwayQualifying diagnosis for the generalized lipodystrophy pathway
    Acquired generalized lipodystrophy (AGL)
    AbbreviationAGL
    DefinitionAn acquired form of generalized lipodystrophy
    Coverage pathwayQualifying diagnosis for the generalized lipodystrophy pathway

    Myalept Initial Approval

    Myalept Initial Approval

    Initial Myalept therapy is approved when all applicable requirements are met and the patient qualifies through at least one indication pathway.

    Myalept initial approval

    • ONE qualifying indication pathway

      • Generalized lipodystrophy pathway

        • The patient has congenital generalized lipodystrophy or acquired generalized lipodystrophy.
        • Leptin deficiency is confirmed by laboratory testing before initiating Myalept.Leptin < 12 ng/mL
        • ONE related complication

    Myalept Renewal

    Myalept Renewal

    Myalept renewal is approved when all of the following conditions are met.

    Myalept renewal

    • The patient was previously approved for Myalept through the plan's prior authorization process.

      Patients not previously approved require initial evaluation review.

    • The patient has demonstrated clinical benefit with Myalept.
    • The patient will continue lifestyle modifications, including diet and exercise, with Myalept.
    • The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist, or has consulted with such a specialist.

    Required Prior Therapy

    StepRequirementFailure criteria
    1Try a conventional agent before Myalept for congenital or acquired generalized lipodystrophy.Inadequate response to the maximum tolerable dose of a conventional agent for complications related to lipodystrophy.

    Dose and Quantity Requirements

    Quantity limits
    AgentMyalept (metreleptin)
    Quantity requirementThe requested quantity or dose must be within FDA labeling
    ApplicabilityThe FDA-labeled dose and quantity must correspond to the requested indication
  1. The requested quantity or dose is within FDA labeling for the requested indication.
  2. Hypertriglyceridemia
    Qualifying thresholdGreater than or equal to 200 mg/dL
    ConditionHypertriglyceridemia related to lipodystrophy
    PathwayQualifying complication under the generalized lipodystrophy pathway
  3. Renewal approval length: 12 months.
  4. Unsupported block type: step_therapy

    Documentation Required

    Generalized Lipodystrophy Documentation

    Document congenital generalized lipodystrophy (CGL) or acquired generalized lipodystrophy (AGL), with leptin deficiency confirmed by laboratory testing before initiating the requested agent.

    • Leptin level must be < 12 ng/mL before treatment initiation.
    • Document at least one related complication: diabetes mellitus, hyperinsulinemia ≥ 30 microU/mL, or hypertriglyceridemia ≥ 200 mg/dL.
    Documentation Required

    Baseline Laboratory and Treatment History

    Before initiating therapy under the generalized lipodystrophy pathway, obtain and document baseline HbA1c, triglycerides, and fasting insulin levels.

    • Baseline results must be measured prior to initiating the requested agent.
    • Include relevant prior treatment response documentation.
    Documentation Required

    Alternative FDA-Labeled Indication Documentation

    For another FDA-labeled indication and route of administration, document an inadequate response to lifestyle modification and the patient's continued commitment to diet modification and exercise with the requested agent.

    • The requested agent must be used for an FDA-labeled indication and route of administration.
    • The prescriber must be a specialist in the area of the diagnosis, such as an endocrinologist, or must have consulted with an appropriate specialist.
    Documentation Required

    Renewal Documentation Required

    Renewal requests must document that the patient was previously approved through the plan's prior authorization process and has experienced clinical benefit with the requested agent.

    • Document continued diet and exercise with therapy.
    • Document specialist prescribing or specialist consultation.
    • Confirm no FDA-labeled contraindication and that the requested quantity or dose remains within FDA labeling for the indication.

    Unsupported block type: denial_risk

    Denial Risk

    Contraindication and Dosing Restrictions

    Confirm that the patient has no FDA-labeled contraindication to the requested agent and that the requested quantity or dose is within FDA labeling for the requested indication.

    • Out-of-label quantity or dosing is not approved.
    • The contraindication and dosing requirements apply to both initial and renewal review.
    Step Therapy

    Lifestyle Modification Required

    The patient must have had an inadequate response to diet modification and exercise when required under the alternative FDA-labeled indication pathway and must continue these lifestyle modifications with the requested agent.

    • Document the inadequate response to lifestyle modification.
    • Document the plan for continued diet and exercise during treatment and renewal.
    Denial Risk

    Missing Generalized Lipodystrophy Criteria

    Requests may be denied when required generalized lipodystrophy criteria are absent or insufficiently documented.

    • No documented diagnosis of congenital generalized lipodystrophy or acquired generalized lipodystrophy.
    • No laboratory-confirmed leptin deficiency before treatment initiation, including a leptin level that is not < 12 ng/mL.
    • No qualifying complication: diabetes mellitus, hyperinsulinemia ≥ 30 microU/mL, or hypertriglyceridemia ≥ 200 mg/dL.
    • Missing baseline HbA1c, triglyceride, or fasting insulin results obtained before treatment.
    • No documented trial of, or inadequate response to, the maximum tolerable dose of a conventional agent for a lipodystrophy-related complication.
    Leptin deficiency
    DefinitionA laboratory-confirmed leptin level below 12 ng/mL
    Testing requirementLeptin deficiency must be confirmed by laboratory testing
    TimingConfirmed before initiating the requested agent
    Diabetes mellitus related to lipodystrophy.
  5. Hyperinsulinemia related to lipodystrophy.≥ 30 microU/mL
  6. Hypertriglyceridemia related to lipodystrophy.≥ 200 mg/dL
  7. Baseline HbA1c, triglycerides, and fasting insulin levels were measured before initiating Myalept.
  8. The patient tried and had an inadequate response to the maximum tolerable dose of a conventional agent for complications related to lipodystrophy.
  9. Other FDA-labeled indication pathway

    • The patient has another FDA-labeled indication for Myalept and the requested route of administration.
    • The patient had an inadequate response to lifestyle modification, including diet modification and exercise.
    • The patient will continue lifestyle modifications with Myalept.
    • The patient does not have partial lipodystrophy, liver disease including NASH or MASH, HIV-related lipodystrophy, or metabolic disease such as diabetes mellitus or hypertriglyceridemia without evidence of generalized lipodystrophy.
  10. Additional requirements

    • The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist, or has consulted with such a specialist.
    • The patient does not have an FDA-labeled contraindication to Myalept.
    • The requested quantity or dose is within FDA labeling for the requested indication.
  11. The patient does not have an FDA-labeled contraindication to Myalept.
  12. The requested quantity or dose is within FDA labeling for the requested indication.